Categories AlphaGraphs, Earnings, Health Care

Amgen swings to profit in Q4, beats estimates

Amgen (AMGN) swung to a profit in the fourth quarter from a loss last year, helped by higher revenues, lower tax rate and a decline in weighted-average shares outstanding. The results exceeded analysts’ expectations. However, the company guided full-year 2019 earnings and revenue below the consensus view.

Net income was $1.93 billion or $3.01 per share compared to a loss of $4.26 billion or $5.89 per share in the previous year quarter. Non-GAAP earnings grew 18% to $3.42 per share.

Total revenues rose 7% to $6.2 billion as new and recently launched products including Repatha, Prolia, Kyprolis, and Xgeva showed double-digit growth.

Looking ahead into the full year 2019, the company expects total revenues in the range of $21.8 billion to $22.9 billion and earnings in the range of $11.55 to $12.75 per share. Non-GAAP earnings are predicted to be in the range of $13.10 to $14.30 per share. Capital expenditures are anticipated to be about $700 million.

Amgen fourth quarter 2018 earnings snapshot
Amgen Q4 2018 Earnings Infographic

For the fourth quarter, Amgen posted sales increases for products such as Repatha, Blincyto, Xgeva, Prolia, Kyprolis, Nplate, Sensipar/Mimpara, Vectibix and Neulasta, driven by higher unit demand. Products such as Epogen, Aranesp, Enbrel, and Neupogen saw sales declines due to lower unit demand and net selling price along with impact from competition.

Research & Development (R&D) expenses increased 13% in the fourth quarter driven by higher spending on business development, its early oncology pipeline, and late-stage development, offset partially by lower spending to support marketed products.

Also read: Amgen Q4 2018 earnings call transcript

During the fourth quarter, Amgen repurchased 11.1 million shares of common stock at a total cost of $2.2 billion. At the end of the quarter, the company had $5.1 billion remaining under its stock repurchase authorization.

Shares of Amgen closed Tuesday’s regular session up 0.08% at $192.11 on the Nasdaq. Following the earnings release, the stock inched down over 2% in the after-market session.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Citigroup (C) reports higher revenue and profit for Q2 2024; earnings beat

Banking behemoth Citigroup Inc. (NYSE: C) Friday reported an increase in revenue and net income for the second quarter of 2024. Earnings came in above analysts’ estimates. Net profit for

Wells Fargo (WFC) Q2 2024 Earnings: Key financials and quarterly highlights

Wells Fargo & Company (NYSE: WFC) reported its second quarter 2024 earnings results today. Total revenue rose 1% year-over-year to $20.7 billion. Net income dropped 1% to $4.9 billion while

JPM Earnings: All you need to know about JPMorgan’s Q2 2024 earnings results

JPMorgan Chase & Co. (NYSE: JPM) reported second quarter 2024 earnings results today. Reported revenue increased 22% year-over-year to $50.2 billion. Managed revenue rose 20% to $51 billion. Net income

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top